First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease
First Tracks Biotherapeutics reported positive top-line results from Cohort 1 of ANB033's Phase 1b celiac disease trial, with statistically significant protection against gluten-induced intestinal damage and symptoms versus placebo. Vh:Cd ratio change was -0.17 on ANB033 versus -0.66 on placebo (p=0.009), and IEL density fell -1.20 versus +18.83 on placebo (p<0.001); ANB033 also blunted symptoms from day one of the 14-day gluten challenge with no serious adverse events.
Key figures
- Drug Name
- ANB033
- Phase Of Trial
- Phase 1b
- Eoe data
- Q3 2027
- Cohort2 data
- Q1 2027
- Cohort1 patients
- 32
- Gluten challenge
- 14-day, 6g daily
- Eoe cohort patients
- 50
- Vciel ls mean change
- -0.25 ANB033 vs -3.59 placebo (delta +3.33, p=0.002)
- Vh cd ls mean change
- -0.17 ANB033 vs -0.66 placebo (delta +0.49, p=0.009)
- Iel density ls mean change
- -1.20 ANB033 vs +18.83 placebo (delta -20.03, p<0.001)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.